Tumors as elusive targets of T-cell-based active immunotherapy
- 1 June 2003
- journal article
- review article
- Published by Elsevier BV in Trends in Immunology
- Vol. 24 (6), 334-341
- https://doi.org/10.1016/s1471-4906(03)00116-9
Abstract
No abstract availableKeywords
This publication has 63 references indexed in Scilit:
- Natural selection of tumor variants in the generation of “tumor escape” phenotypesNature Immunology, 2002
- Kinetics of cytokine expression in melanoma metastases classifies immune responsivenessInternational Journal of Cancer, 2001
- Two subsets of memory T lymphocytes with distinct homing potentials and effector functionsNature, 1999
- Exploring the new world of the genome with DNA microarraysNature Genetics, 1999
- Supraoptimal Peptide–Major Histocompatibility Complex Causes a Decrease in Bcl-2 Levels and Allows Tumor Necrosis Factor α Receptor II–mediated Apoptosis of Cytotoxic T LymphocytesThe Journal of Experimental Medicine, 1998
- Implications for immunosurveillance of altered HLA class I phenotypes in human tumoursImmunology Today, 1997
- Cancer as a complex adaptive systemMedical Hypotheses, 1996
- T Cell Activation Determined by T Cell Receptor Number and Tunable ThresholdsScience, 1996
- Different responses are elicited in cytotoxic T lymphocytes by different levels of T cell receptor occupancy.The Journal of Experimental Medicine, 1996
- Loss of HLA class I antigens by melanoma cells: molecular mechanisms, functional significance and clinial relevanceImmunology Today, 1995